HCL-GROUP
Water security has never been more urgent. With the global population set to hit 8.5 billion by 2030, pressure is increasing on the world’s limited supply of freshwater. By 2030, the global demand for water will have exceeded sustainable supply by 40%. In addition to immediate and dire consequences to people’s health and food production, a lack of access to clean water can limit economic growth by up to one-third , as well as have adverse effects on natural biodiversity and social fabrics. Governments and businesses must bring freshwater to the forefront of their strategies, and innovation will play a key role in their success.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220524005757/en/
To drive the freshwater conservation and management agenda, leading global conglomerate HCL has partnered with UpLink, the open innovation platform of the World Economic Forum that connects highly-promising start-ups with the partners and funding they need to scale. Through a $15 million investment over five years, HCL will help accelerate the innovation agenda for water and create a first-of-its-kind innovation ecosystem for the global freshwater sector on UpLink, called the ‘Aquapreneur Innovation Initiative’.
This initiative will draw on HCL’s own regional experience of driving innovative projects in water conservation and brings global leaders and champions together, to foster multi-stakeholder collaboration. In building this ecosystem, water entrepreneurs will be able to thrive and influence freshwater ecosystems all over the world.
“Today, freshwater resources globally are extremely burdened and every fifth child on this planet faces water scarcity,” said Roshni Nadar Malhotra, CEO of HCL Group and Chairperson of HCL Technologies . “At HCL we want to make every effort to help resolve this global crisis. Our partnership with World Economic Forum’s UpLink platform is a step in this direction and our ecosystem approach can be truly transformative. Together we will not just encourage and scale innovations in this critical area, but also help build capacity amongst water-focused entrepreneurs - aquapreneurs - to execute on the innovative solutions. Through the Aquapreneur Innovation Initiative, we are re-committing to accelerate multi-stakeholder collaboration and innovation in the global freshwater conservation space.”
HCL’s new collaboration with UpLink will encompass building the freshwater innovation ecosystem including: running innovation challenges to source solutions from ‘aquapreneurs’ (water focused entrepreneurs), connecting these aquapreneurs to existing initiatives and water networks, unlocking funding opportunities to scale their ventures and raising awareness on the global agenda on the importance of freshwater.
Together, HCL & UpLink will also aim to help aquapreneurs build their skills and leadership capacity. Combined, these efforts will help drive and accelerate the innovation agenda for water and the sector’s mainstream ideas, approaches and solutions.
“The Aquapreneur Innovation Initiative comes at a critical time,” said Olivier Schwab, Managing Director, World Economic Forum. “With water scarcity enveloping regions around the world, we need to fast-track progress within the freshwater sector and build security for people and planet. HCL’s collaboration with UpLink will harness and drive forward the solutions of the world’s top innovators, connecting them to the initiatives and networks which can see them scale and drive transformational change for the world’s most fragile water systems.”
Innovation in freshwater management is also critical for water’s role in the transition to a green economy, as highlighted in the release of a new report in Davos today, A Freshwater Future: Without Blue, There Is No Green Economy .
UpLink was launched at the World Economic Forum Annual Meeting 2020 in collaboration with founding partners, Salesforce and Deloitte. The platform sources new innovations through a competition framework known as innovation challenges. UpLink has now run more than 30 challenges and identified over 260 entrepreneurs with innovative solutions for the world’s most pressing issues.
About HCL Group
Founded in 1976 as one of India’s original IT garage start-ups, HCL is a pioneer of modern computing with many firsts to its credit, including the introduction of the 8-bit microprocessor-based computer in 1978 well before its global peers. Today, the HCL Group has business presence across sectors including technology and healthcare and comprises three group companies – HCL Technologies, HCL Infosystems and HCL Healthcare. The Group generates annual revenues of over US$11.5 billion with more than 209,000 employees operating across 52 countries.
HCL Technologies, a group company, empowers global enterprises with technology for the next decade, today. As a leading global technology company, it takes pride in its diversity, social responsibility, sustainability and education initiatives. HCL Technologies is also a strategic partner of the World Economic Forum.
For further information, visit www.hcl.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220524005757/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Natus Sensory Appoints Arne Boye Nielsen to Board of Directors8.1.2026 08:00:00 CET | Press release
Natus Sensory, a global leader in sensory and diagnostic solutions, today announced the appointment of Arne Boye Nielsen to its Board of Directors, effective January 1, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107392331/en/ Arne Boye Nielsen Arne brings more than 30 years of executive leadership experience in diagnostics and medical technology, most notably as President of Demant Diagnostics, where he built and scaled the business into a global leader over three decades. During his tenure, Arne played a central role in shaping Demant Diagnostics’ long-term strategy, portfolio expansion, and international growth, establishing it as a cornerstone of Demant’s global healthcare footprint. In addition to his executive leadership background, Arne brings extensive board experience. His deep expertise across diagnostics, governance, and value creation will further strengthen Natus Sensory’s Board as the company contin
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
